Wilmington Healthcare-pharmaphorum conference: England’s NHS is moving towards integrated care, and long-term outcomes-based contracts for medicines could become the norm
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.
